These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 20516273)
1. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Zvada SP; Van Der Walt JS; Smith PJ; Fourie PB; Roscigno G; Mitchison D; Simonsson US; McIlleron HM Antimicrob Agents Chemother; 2010 Aug; 54(8):3390-4. PubMed ID: 20516273 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. Keung AC; Owens RC; Eller MG; Weir SJ; Nicolau DP; Nightingale CH Antimicrob Agents Chemother; 1999 May; 43(5):1230-3. PubMed ID: 10223941 [TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Savic RM; Lu Y; Bliven-Sizemore E; Weiner M; Nuermberger E; Burman W; Dorman SE; Dooley KE Antimicrob Agents Chemother; 2014 Jun; 58(6):3035-42. PubMed ID: 24614383 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Langdon G; Wilkins J; McFadyen L; McIlleron H; Smith P; Simonsson US Antimicrob Agents Chemother; 2005 Nov; 49(11):4429-36. PubMed ID: 16251279 [TBL] [Abstract][Full Text] [Related]
7. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. Hibma JE; Radtke KK; Dorman SE; Jindani A; Dooley KE; Weiner M; McIlleron HM; Savic RM Am J Respir Crit Care Med; 2020 Sep; 202(6):866-877. PubMed ID: 32412342 [No Abstract] [Full Text] [Related]
8. Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. Conte JE; Golden JA; McQuitty M; Kipps J; Lin ET; Zurlinden E Antimicrob Agents Chemother; 2000 Apr; 44(4):985-90. PubMed ID: 10722501 [TBL] [Abstract][Full Text] [Related]
9. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S; Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821 [TBL] [Abstract][Full Text] [Related]
11. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. Keung A; Reith K; Eller MG; McKenzie KA; Cheng L; Weir SJ Int J Tuberc Lung Dis; 1999 May; 3(5):426-36. PubMed ID: 10331733 [TBL] [Abstract][Full Text] [Related]
12. Single-dose pharmacokinetics of rifapentine in women. Keung AC; Eller MG; Weir SJ J Pharmacokinet Biopharm; 1998 Feb; 26(1):75-85. PubMed ID: 9773393 [TBL] [Abstract][Full Text] [Related]
13. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Keung A; Eller MG; McKenzie KA; Weir SJ Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734 [TBL] [Abstract][Full Text] [Related]
14. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286 [TBL] [Abstract][Full Text] [Related]
15. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. Savic RM; Weiner M; MacKenzie WR; Engle M; Whitworth WC; Johnson JL; Nsubuga P; Nahid P; Nguyen NV; Peloquin CA; Dooley KE; Dorman SE; Clin Pharmacol Ther; 2017 Aug; 102(2):321-331. PubMed ID: 28124478 [TBL] [Abstract][Full Text] [Related]
16. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Langdon G; Wilkins JJ; Smith PJ; McIlleron H Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278 [TBL] [Abstract][Full Text] [Related]
17. Single-dose pharmacokinetics of rifapentine in elderly men. Keung AC; Eller MG; Weir SJ Pharm Res; 1998 Aug; 15(8):1286-91. PubMed ID: 9706063 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Zhu M; Nix DE; Adam RD; Childs JM; Peloquin CA Pharmacotherapy; 2001 Aug; 21(8):891-7. PubMed ID: 11718495 [TBL] [Abstract][Full Text] [Related]
19. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Francis J; Zvada SP; Denti P; Hatherill M; Charalambous S; Mungofa S; Dawson R; Dorman S; Gupte N; Wiesner L; Jindani A; Harrison TS; Olagunju A; Egan D; Owen A; McIlleron HM Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670438 [TBL] [Abstract][Full Text] [Related]
20. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Egelund EF; Weiner M; Singh RP; Prihoda TJ; Gelfond JA; Derendorf H; Mac Kenzie WR; Peloquin CA Antimicrob Agents Chemother; 2014 Aug; 58(8):4904-10. PubMed ID: 24841270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]